[Complications in the treatment of ocular surface squamous neoplasia with interferon α‑2b in rheumatoid arthritis].
BACKGROUND
Interferon α‑2b (IFN α‑2b) is an established and well-tolerated treatment for ocular surface squamous neoplasia (OSSN).


METHODS
Report of complications in two patients with OSSN and rheumatoid arthritis treated with adjuvant topical IFN α‑2b.


RESULTS
One patient developed a scleral melt and the other one severe keratitis. After discontinuing treatment with IFN α‑2b both patients showed considerable improvement.


CONCLUSIONS
Immunosuppressed patients with OSSN under topical IFN α‑2b should be closely monitored for early detection of complications.
Augenklinik, Krankenhaus Merheim, Kliniken der Stadt Köln, Ostmerheimer Str. 200, 51109, Köln, Deutschland. elenatorres@web.de.
E
E
Torres Suárez
Augenklinik, Krankenhaus Merheim, Kliniken der Stadt Köln, Ostmerheimer Str. 200, 51109, Köln, Deutschland.
R
R
Pinheiro
Augenklinik, Krankenhaus Merheim, Kliniken der Stadt Köln, Ostmerheimer Str. 200, 51109, Köln, Deutschland.
N
N
Schrage
D000368:Aged; D001172:Arthritis, Rheumatoid / Q000150:complications*; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000188:drug therapy*; D003230:Conjunctival Neoplasms / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use*; D007634:Keratitis / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control; D008875:Middle Aged; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012591:Scleral Buckling; D015422:Scleral Diseases / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control; D016896:Treatment Outcome
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Complications; IFN α‑2b; Immune suppression; Ocular surface squamous neoplasia; Rheumatoid arthritis